Objective: Magnesium supplementation has been reported to have a nephroprotective effect on cisplatin-induced renal dysfunction, but little evidence exists regarding the effect of magnesium preloading before cisplatin administration. We started to include magnesium preloading (8 mEq) in cisplatin-containing treatment regimens in January 2011. The aim of the present study was to evaluate whether magnesium preloading reduces cisplatin-induced nephrotoxicity. Methods: We retrospectively reviewed 496 thoracic malignancy patients treated with cisplatin (60 mg/m 2 )-containing regimens as a first-time chemotherapy between January 2009 and December 2011. We compared the incidence of Grade 2 serum creatinine elevation according to the Common Terminology Criteria for Adverse Events, version 4.0, between magnesium preloading group (n ¼ 161 [32%]) and non-magnesium preloading group (n ¼ 335 [68%]) during the first cycle and all cycles. Results: The median number of administered cycles was four in both groups. The incidence of Grade 2 serum creatinine elevation in magnesium preloading group was significantly lower during both the first cycle and all cycles than in the non-magnesium preloading group (4.9 versus 19.1% during the first cycle, and 14.2 versus 39.7% during all the cycles). A multivariate analysis indicated that magnesium preloading significantly reduced cisplatin-induced nephrotoxicity throughout the entire period from after the first administration (odds ratio: 0.262, 95% confidence interval: 0.106 -0.596 during the first cycle, and odds ratio: 0.234, 95% confidence interval: 0.129 -0.414 during all cycles). Conclusions: Magnesium preloading before cisplatin administration significantly reduced cisplatin-induced nephrotoxicity.
INTRODUCTION
Cisplatin is one of the most potent and valuable chemotherapy agents available, and is used to treat a broad spectrum of malignancies, with cisplatin-containing regimen being one of the optimal treatments for patients with thoracic malignancy such as lung cancer, thymic malignancies and pleural mesothelioma. Nephrotoxicity caused by cisplatin is a well-known side effect and is dose-limiting toxicity that most commonly manifests as an acute and chronic impairment of renal function in almost all cisplatin-containing regimens. Nephrotoxicity appears to be clinical problem in 28 -42% of patients treated with cisplatin in clinical practice (1) (2) (3) .
Cisplatin induces the formation of DNA intrastrand crosslinks, resulting in cytotoxicity in tumors and other dividing cells, and these crosslinks are responsible for arresting cancer cell proliferation (4) . More than 50% of the administered cisplatin is excreted in the urine during the first 24 h following cisplatin administration. However, the concentration of platinum in the renal cells is several fold greater than in the plasma and other organs (5) . Because of this disproportionate accumulation, cisplatin primarily injures the proximal tubule cells selectively, as manifested by both necrosis and apoptosis, causing a decrease in the glomerular filtration rate (GFR), even though non-proliferating cells are generally less sensitive to the toxicity of cisplatin (6) .
The mechanism by which cisplatin causes renal cell injury has multiple intracellular effects, including the regulation of genes, the induction of direct cytotoxicity with reactive oxygen species, the activation of mitogen-activated protein kinase, mitochondrial dysfunction, apoptosis and the simulation of inflammation and fibrogenesis (7 -9) . Direct cytotoxic damage to the proximal tubule, especially in the S3 segment and in the thick ascending limb of the loop of Henle or in the distal parts of the nephron segment (10) , also causes tubular reabsorption defects, resulting in an electrolyte concentration defect. The major electrolyte abnormality due to tubular reabsorption defects and urinary wasting is hypomagnesemia, which is observed in 50% of patients treated with cisplatincontaining regimens (10 -12) . Hypomagnesemia itself enhances cisplatin-induced nephrotoxicity in addition to the direct cytotoxic damage of cisplatin to renal cells (13) . Cisplatin treatment also produces gastrointestinal side effects, which might lead to greater Mg depletion through diarrhea and anorexia. Eventually, patients with such side effects could be rendered more susceptible to the nephrotoxicity of cisplatin. Therefore, the Mg status during cisplatin treatment is thought to be associated with nephrotoxicity.
Based on this background, several clinical trials to investigate the role of Mg supplementation in cisplatin-induced nephrotoxicity have been performed, revealing that magnesium supplementation before and after the administration of cisplatin had preventive effect on hypomagnesemia and cisplatin-induced nephrotoxicity (3, 14) . The cisplatin template of the national comprehensive cancer network (NCCN) recommended hyper diuresis using magnesium supplementation (8 mEq) before the administration of cisplatin. However, these trials included small numbers of patients on a scale of ,50 patients, limiting the certainty of results regarding the nephroprotective effect of Mg supplementation during chemotherapy.
The aims of the present study were to evaluate the effect of Mg-preloading on cisplatin-induced nephrotoxicity in patients with thoracic malignancy and to assess whether Mg preloading reduced cisplatin-induced nephrotoxicity, compared with the incidence of nephrotoxicity associated with non-Mg preloading regimen.
PATIENTS AND METHODS

PATIENTS
We retrospectively reviewed consecutive thoracic malignancy patients who were treated with cisplatin (60 mg/m 2 )-containing regimen as first-line chemotherapy, including adjuvant chemotherapy, between January 2009 and December 2011 at the National Cancer Center Hospital East. Patients whose treatment methods, including antiemetic treatment and Mg preloading, were changed during the cisplatin-containing chemotherapy, were excluded from this study. To evaluate the Mg preloading effect on cisplatin-induced nephrotoxicity, the patients were divided into two groups, non-Mg preloading group (January 2009 -December 2010) and Mg preloading group (January 2011 -December 2011), since we began using Mg preloading (8 mEq) in conjunction with cisplatincontaining regimens in January 2011 based on the cisplatin template of NCCN recommendation.
HYDRATION AND TREATMENT METHODS
Cisplatin (60 mg/m 2 ) was administered over 60 min on Day 1 in combination with other chemotherapeutic agents, mannitol and 2500 ml of hydration. In the Mg preloading group, patients received a solution consisting of 500 ml of isotonic saline plus 8 mEq of magnesium sulfate before the administration of cisplatin over 60 min. There was no difference between the groups with respect to the volume of hydration on the day of cisplatin administration, except for the Mg preloading, for both regimens. On Days 2 -3, 1000 ml of intravenous infusion fluids were administered. The reduction of the cisplatin dose and the discontinuation of the cisplatin-containing regimen depended on the physician's discretion, based on the adverse events associated with the cisplatin-containing regimen and the response to chemotherapy. Antiemetic prophylaxis consisted of 5-HT 3 receptor antagonist (granisetron, 1 mg) and dexamethasone (13.2 mg on Day 1, 9.9 mg on Days 2 -4). From January 2011, aprepitant (125 mg on Day 1, 80 mg on Days 2 -3) was added as an antiemetic treatment to the administration of a 5-HT 3 receptor antagonist and dexamethasone in the cisplatin-containing regimen.
NEPHROTOXICITY EVALUATION
Renal function was evaluated based on the serum creatinine (sCr, mg/dl) level. We used the changes in sCr as measure of nephrotoxicity. In this present study, nephrotoxicity arising from the cisplatin-containing regimen was defined as Grade 2 or more sCr elevation according to Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. We evaluated the association between the incidence of Grade 2 or more sCr elevation during first-time chemotherapy and the effect of Mg preloading. Creatinine clearance (Ccr) was assessed using the Cockroft-Gault formula.
DATE COLLECTION AND STATISTICAL ANALYSIS
The clinical characteristics before the start of cisplatincontaining chemotherapy [age, sex, performance status (PS), complication with diabetes mellitus (DM), hemoglobin (Hb, g/dl), serum albumin (Alb, g/dl), Ccr (mg/dl), serum sodium (Na, mEq/l), serum potassium level (K, mEq/l) and complication with pleural effusion] and the treatment methods [adjuvant chemotherapy setting, cisplatin dose, concurrent thoracic radiotherapy (TRT), use of aprepitant, preloading Mg before chemotherapy and co-administration of non-steroidal antiinflammatory agents (NSAIDs)] were retrospectively obtained from the patients' medical records. Differences in categorical outcomes were evaluated using the x 2 test or the Fisher's exact test, as appropriate. The median change in the sCr level between the Mg preloading and the non-Mg preloading groups was analyzed using the Mann -Whitney U test. Multivariate analyses were performed using logistic regression with the patient characteristics and treatment methods as covariates. Candidate covariates were entered into the multivariate model if P , 0.05 in a univariate analysis. All the P values that were reported were two-sided, and the significance level was set at ,0.05. All the statistical analyses were performed using JMP for Windows, version 9, statistical software package (SAS Institute, NC, USA). This study was approved by the Institutional Review Board of the National Cancer Center.
RESULTS
PATIENT CHARACTERISTICS
Of the 521 thoracic malignancy patients who were treated with cisplatin-containing regimen during the study period, Ccr was estimated using the Cockroft-Gault formula. Table 2 . The median number of administered cycles was four in both groups. The most common cisplatin-containing regimen was cisplatin plus vinorelbine in both groups. Concurrent thoracic radiation therapy was significantly more frequent in the non-Mg group, and the co-administration of NSAIDs was significantly more frequent in the non-Mg group.
INCIDENCE OF CISPLATIN-INDUCED NEPHROTOXICITY
The median maximum serum creatinine level (CRN max ) was 0.9 mg/dl (range: 0.5 -5.6 mg/dl) in the Mg preloading group and 0.9 mg/dl (range: 0.5 -3.5 mg/dl) in the non-Mg preloading group during the first cycle and 0.9 mg/dl (range: 0.6 -5.6 mg/dl) in the Mg preloading group and 1.1 mg/dl (range: 0.5 -3.5 mg/dl) in the non-Mg preloading group during all the cycles. The CRN max in the Mg preloading group was significantly lower than that in the non-Mg preloading group during both the first cycle (P , 0.001) and all the cycles (P , 0.001) ( Figure 1A and B) . The incidence of a Grade 2 or worse sCr elevation was 4.9% in the Mg preloading group and 19.1% in the non-Mg preloading group during the first cycle and 11.8% in the Mg preloading group and 39.7% in the non-Mg preloading group during all cycles (Figure 2A and B) . Mg preloading significantly reduced the incidence of Grade 2 or worse sCr elevation throughout the entire treatment period after the first administration (P , 0.001). The incidence of a Grade 1 sCr elevation is higher in the non-Mg preloading group than the Mg proportion group during the first cycle (62.4 versus 46.0%), while slightly lower in the non-Mg preloading group than the Mg preloading group during all cycles (51.6 versus 53.0%) due 
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to the remarkably increase of Grade 2 or worse sCr elevation in non-Mg preloading group after the first cycle.
UNIVARIATE AND MULTIVARIATE ANALYSIS OF RISK FACTORS FOR CISPLATIN-INDUCED NEPHROTOXICITY
The results of univariate analyses to identify risk factors for cisplatin-induced nephrotoxicity during the first cycle and all cycles are shown in Tables 3 and 4 . The multivariate analysis showed sex, Mg preloading, the co-administration of NSAIDs and the Ccr to be significant independent risk factors for cisplatin-induced nephrotoxicity during the first cycle. Hb, Mg preloading, and the co-administration of NSAIDs were significant independent risk factors for cisplatin-induced nephrotoxicity in all the cycles. Mg preloading significantly reduced cisplatin-induced nephrotoxicity throughout the entire treatment period after the first administration [odds ratio (OR): 0.283, 95% confidence interval (CI): 0.117 -0.628 during the first cycle, and OR: 0.264, 95% CI: 0.148 -0.458 during all the cycles, respectively].
DISCUSSION
In the current study, we analyzed the preventive effect of Mg preloading on cisplatin-induced nephrotoxicity in thoracic malignancy patients treated with cisplatin-containing regimens and found that Mg preloading (8 mEq) significantly reduced cisplatin-induced nephrotoxicity throughout the entire treatment period after the first administration. So far, several prospective clinical trials have revealed that Mg supplementation has a preventive effect on cisplatin-induced nephrotoxicity. Willox et al. (14) double-blind, placebo-controlled, randomized study (3) . The outcomes of these trials agreed with the results of the present study. However, these trials had small sample sizes on the scale of ,50 cases. Also, the doses and methods of magnesium supplementation varied, including administration before and/or after cisplatin administration, and the appropriate administration method for Mg preloading remained unclear. We have administered 8 mEq of Mg just before cisplatin administration in patients with thoracic malignancies since January 2011. Then, we retrospectively compared renal function between the non-Mg preloading group and the Mg preloading group. Although this present study had retrospective design, it is the first to report preventive effect of Mg on cisplatin-induced nephrotoxicity in a study with a scale of over 150 patients.
Magnesium is the second most common intracellular cation in the human body and is an active participant in numerous cellular processes. Mg plays a role as cofactor for about 300 cellular enzymes, participating in reactions concerning cellular energy metabolism involving ATP, muscle Na K-pump activity, calcium channel activity, stabilization of membrane structures and mRNA translation as well as the transcription and replication of DNA (15 -17) . Mg homeostasis is closely regulated by the kidney, with two-thirds of the total serum Mg being filtered at the glomeruli as part of filtration -reabsorption process (17) . Under normal conditions, reabsorption takes place primarily in the wide ascending limb of the loop of Henle (70%) and proximal tubule (15%). The direct damage of cisplatin to these tubular cells causes urinary Mg wasting and occurs in approximately half of patients treated with cisplatin-containing regimens, although the cellular alterations of cisplatin leading to renal magnesium wasting are not well understood.
Regarding the role of Mg in renal function during cisplatin treatment, an experimental rat model study has indicated a substantial additive effect of Mg depletion on cisplatininduced renal toxicity, as evidenced by significant changes in plasma creatinine and urea (13) . As with cisplatin treatment, renal Mg wasting is common in cyclosporine and tacrolimustreated recipients, presumably because of drug effects on Mg Ccr was estimated using the Cockroft-Gault formula. Effect of Mg on CDDP-induced nephrotoxicity reabsorption (18) . Hypomagnesemia has been implicated as a contributor to the nephrotoxicity associated with cyclosporine (19) . A rat experimental model study revealed that Mg supplementation is a crucial factor in protecting against the nephrotoxic actions of cyclosporine A in cell lines isolated from rat proximal tubules (20) , and Mg supplementation reduced cyclosporine A induced nephrotoxicity (21) . Therefore, Mg supplementation could reduce Mg depletion that has been induced by drugs such as cisplatin and cyclosporine and could prevent drug-induced nephrotoxicity. In this study, Mg preloading was found to have preventive effect on cisplatin-induced nephrotoxicity, but it is unclear whether Mg supplementation had an impact on the tumor response because this study contained a variety of patients with different clinical characteristics. In both in vitro and in vivo studies, Mg supplementation has been reported to affect tumor growth, and magnesium depletion reportedly decreases tumor growth (22) . However, there were no studies on the free platinum and total platinum concentration in patients treated with magnesium supplementation before cisplatin. The relationship between the pharmacokinetics of cisplatin and magnesium supplementation is unclear. On the other hands, the previous prospective clinical trials and retrospective studies indicated that Mg supplementation did not affect tumor response of cisplatin-based chemotherapy (3, 14, 23) . In future studies, an evaluation of the association between the Mg status, pharmacokinetics of cisplatin and tumor response, including the preventive effect of Mg preloading, is needed.
This retrospective study had some limitations regarding the evaluation of the preventive effect of Mg preloading. First, we did not validate the association between cisplatin-induced nephrotoxicity and the serum or urinary Mg level. A second limitation is that several cisplatin-containing regimens were included in this study. In thoracic malignancy patients, the treatment regimens differ depending on the clinical stage and histology. Third, risk factors for the development of cisplatin-induced nephrotoxicity reportedly include older age, female gender, current smoking status and low serum Alb level. Therefore, to exclude the possibility that the patient characteristics and treatment methods might have affected the renal toxicity caused by cisplatin, we evaluated risk factors of renal dysfunction such as age, sex, creatinine clearance, complicated pleural effusion, DM, co-administration of NSAIDs and electrolyte abnormality before treatment, and a multivariate analysis using a multiple regression method was performed. The risk factors for cisplatin-induced nephrotoxicity other than Mg preloading were sex, Ccr, co-administration of NSAIDs during the first cycle, Hb and the co-administration of NSAIDs during all the cycles.
In conclusion, Mg preloading had a preventive effect on cisplatin-induced nephrotoxicity. However, the appropriate dose for Mg preloading and the utility of Mg supplementation before and after cisplatin administration remain unclear. Also, some patients treated with Mg preloading regimen still developed cisplatin-induced nephrotoxicity, and further methods of preventing cisplatin-induced nephrotoxicity, including Mg preloading, need to be investigated.
Funding
This work was supported in part by a grant-in-aid for Cancer Research (20S-2) from the Ministry of Health, Labour and Welfare of Japan. Jpn J Clin Oncol 2014;44(4) 353
